You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)料首季虧損收窄 收入按年增最少89%
阿思達克 03-20 10:23
君實生物(01877.HK)就A股發行上市的首次公開發行股票並在科創板上市的招股說明書(上會稿)於昨日(19日)刊載於上交所科創板股票發行上市審核網站,當中載有若干公司2020年一季度主要財務資料初步測算情況。

有關資料顯示,公司預料3月底止首季錄歸屬公司普通股股東淨虧損介乎1.98億元人民幣(下同)至2.33億元,較去年同期虧損3.71億元收窄。季內營業收入料介乎1.5億元至2億元,較去年同期增加89.7%至153%。

收入增長主要原因為產品「特瑞普利單抗」於2018年12月正式獲得國家藥品監督管理局有條件批准上市並於2019年2月末起開展銷售。

公司指,上述根據中國企業會計準則編製的預計情況,未經審計或審閱,亦不代表公司最終可實現的營業收入和淨利潤。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account